PTGIR - Prostacyclin Receptor | Elisa - Clia - Antibody - Protein

Background

The Prostacyclin Receptor (PTGIR), also known as the prostacyclin receptor (IP receptor), is a G protein-coupled receptor (GPCR) primarily involved in mediating the effects of prostacyclin (PGI2), a potent vasodilator and inhibitor of platelet aggregation. PTGIR is a GPCR that responds to prostacyclin (PGI2), a prostaglandin synthesized from arachidonic acid by the action of cyclooxygenase enzymes. PTGIR is expressed in various tissues and cell types, including vascular endothelial cells, smooth muscle cells, platelets, and immune cells. PTGIR is activated by prostacyclin (PGI2), a lipid mediator with diverse physiological effects, including vasodilation, inhibition of platelet aggregation, and modulation of inflammation. In summary, the Prostacyclin Receptor (PTGIR) plays crucial roles in mediating the physiological effects of prostacyclin (PGI2), including vasodilation, inhibition of platelet aggregation, and modulation of inflammation. Dysregulation of PTGIR signaling is implicated in cardiovascular diseases, pulmonary hypertension, and inflammatory disorders, highlighting its therapeutic potential as a target for pharmacological intervention

Structural Features:

• PTGIR is a typical GPCR with seven transmembrane domains, an extracellular N-terminus, and an intracellular C-terminus.
• Ligand binding induces conformational changes in the receptor, leading to activation of downstream signaling pathways.

Physiological Functions:

• Vasodilation: PTGIR activation mediates vasodilation in blood vessels, contributing to the regulation of blood pressure and blood flow.
• Platelet Inhibition: PTGIR signaling inhibits platelet activation and aggregation, reducing the risk of thrombosis and cardiovascular events.
• Anti-inflammatory Effects: Prostacyclin signaling through PTGIR has anti-inflammatory effects, modulating immune cell function and cytokine production.

Clinical Implications:

• Cardiovascular Protection: Activation of PTGIR protects against cardiovascular diseases such as hypertension, atherosclerosis, and thrombosis.
• Pulmonary Hypertension: Dysfunction of PTGIR signaling is implicated in pulmonary hypertension, and PTGIR agonists are used for its treatment.
• Inflammatory Disorders: Altered PTGIR expression or function may contribute to inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

Therapeutic Potential:

• Cardiovascular Therapy: PTGIR agonists are used in the treatment of pulmonary hypertension and other cardiovascular disorders.
• Antiplatelet Therapy: Modulation of PTGIR signaling pathways may offer therapeutic strategies for the prevention of thrombosis and cardiovascular events.
• Anti-inflammatory Agents: Targeting PTGIR signaling could be explored for the development of anti-inflammatory drugs for various inflammatory disorders.